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Angiogenesis plays an essential role in several diseases of the eye and in the growth of solid 
tumors, but existing antiangiogenic therapies have limited benefits in several cases.  
We report the antiangiogenic effects of a monoclonal antibody, CL1-R2, in several animal 
models of neovascularization. CL1-R2 recognizes human CD160, a membrane receptor 
which is conserved in various mammal species. We show that CD160 is expressed on the 
endothelial cells of newly formed blood vessels in human colon carcinoma and mouse B16 
melanoma but not in vessels of healthy tissues. CL1-R2 reduced fibroblast growth factor 
2–induced neovascularization in the rabbit cornea, in a mouse model of oxygen-induced 
retinopathy, and in a mouse Matrigel plug assay. Treatment of B16 melanoma-bearing mice 
with CL1-R2 combined with cyclophosphamide chemotherapy caused regression of the 
tumor vasculature and normalization of the remaining vessels as shown by Doppler ultrasono-
graphy, intravital microscopy, and histology. These studies validate CD160 as a potential  
new target in cases of human pathological ocular and tumor neoangiogenesis that do not 
respond or become resistant to existing antiangiogenic drugs.
© 2011 Chabot et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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highly restricted (Anumanthan et al., 1998). We found that 
CD160 is expressed by growing but not quiescent endothelial 
cells in culture (Fons et al., 2006). Second, using in vitro assays, 
we have demonstrated that CL1-R2, an IgG1 mAb directed 
against human CD160 which recognizes both human and 
murine CD160 (Fig. S1), had antiangiogenic properties, in-
ducing caspase-dependent endothelial cell apoptosis, without 
the  need  for  Fc  receptor–bearing  cytotoxic  immune  cells 
(Fons et al., 2006). Third, the CD160 gene is not only present 
in the human genome but is conserved in several mammalian 
species, including rabbits and mice (Maeda et al., 2005; Fons 
et al., 2006), thus allowing in vivo experiments on these ani-
mals. In this paper, we bring the proof of principle of the   
in vivo antiangiogenic therapeutic efficacy of CL1-R2 in dif-
ferent animal models of ocular and tumor neovascularization. 
In mouse transplanted B16 melanoma tumors, as well as in   
a transplant model of anaplastic lymphoma kinase (ALK)-
induced fibroblast tumors in athymic nude mice (Giuriato et al., 
2007), CL1-R2 not only inhibits tumor vascular density but 
also normalizes the structure of the remaining vessels, allow-
ing better delivery of a chemotherapeutic agent.
RESULTS
The CL1-R2 mAb inhibits ocular neovascularization in rabbit 
cornea and oxygen-induced retinopathy in a mouse model
We evaluated the antiangiogenic properties of CL1-R2 mAb 
in vivo by using two different ocular neoangiogenesis animal 
models. The vertebrate eye has an advantage for these studies 
in that it is considered to be an immunoprivileged site 
(Cursiefen, 2007), thus possibly devoid of immune cells that 
could bind CL1-R2. We first used a rabbit corneal pocket assay 
(Fons et al., 2006) to determine whether CL1-R2 inhibits   
fibroblast growth factor 2 (FGF2)–induced corneal neovascu-
larization. The cornea is normally devoid of both blood and 
lymphatic vessels and actively maintains this avascularity 
(Cursiefen, 2007). In this model, neovessels are attracted from 
the limbus. Neovascularization was assessed 8 d after transplanta-
tion of corneal implants containing FGF2 and two subconjunc-
tival injections of 100 µg CL1-R2 or control IgG1. Treatment 
with CL1-R2 significantly decreased corneal neovascularization 
when compared with control IgG1-treated rabbits (Fig. 1, 
A and B). These findings indicate that CL1-R2 treatment 
inhibits growth factor–induced corneal neovascularization.
Next, we investigated the effect of CL1-R2 in a mouse 
model of human retinopathy of prematurity by exposing pre-
mature newborn mice (postnatal day (P) 7–12) to high oxygen 
levels (Smith et al., 1994; Economopoulou et al., 2005). In 
100% of these animals the return to normoxic conditions in-
duced retinal ischemia and VEGF-dependent preretinal vas-
cularization. We first performed a qualitative assessment of the 
retinal vasculature on flat-mounted FITC-dextran–perfused 
whole retinas after intravitreal injections of CL1-R2 or con-
trol IgG1 (Fig. 2 A). Retinas from normal untreated animals 
exhibited  normal  vascularization,  i.e.,  both  superficial  and 
deep vascular layers which extended from the optic nerve to 
the periphery. The vessels formed a radial branching pattern 
Angiogenesis, the formation of new blood vessels from 
the preexisting vasculature, occurs physiologically during em-
bryogenesis, the menstrual cycle, and wound healing (Carmeliet, 
2005), but it is also important in certain pathologies, notably 
in ocular neovascular diseases (a leading cause of vision loss in 
the world; Sherris, 2007) and in tumor growth, invasion, and 
metastasis (Carmeliet, 2005). Tumor-induced angiogenesis is a 
major obstacle to successful immune therapy, as it prevents 
both migration of immune effector cells into established solid 
tumors and delivery of chemotherapeutic drugs (Buckanovich 
et al., 2008). Various therapies that limit angiogenesis are being 
pursued (Shojaei and Ferrara, 2007), including mAbs and small 
molecule inhibitors (Folkman, 2007; Cao, 2009; Pàez-Ribes 
et al., 2009; Takeda et al., 2009). Of these, mAbs used alone or 
in combination with other drugs have proven to be the most 
successful for treating ocular neovascularization and tumor 
growth (Ma and Adjei, 2009).  Various engineered mAbs are in 
clinical use to block angiogenic factors such as vascular endo-
thelial growth factor (VEGF) or VEGF receptor 2, thus abro-
gating VEGF signaling (Ma and Adjei, 2009). The humanized 
IgG1 mAb against VEGF-A, bevacizumab (Avastin), and its 
derivative ranibizumab (Lucentis; Genentech and Novartis), 
which has a smaller molecular mass and a higher affinity for 
VEGF, were approved by the FDA (Rosenfeld et al., 2006) as 
intravitreal injections for the treatment of several ocular neo-
vascular diseases including subfoveal neovascular wet age- 
related macular degeneration (AMD; Rosenfeld et al., 2006), 
diabetic retinopathies (Fletcher and Chong, 2008), neovascu-
lar glaucoma (Duch et al., 2009; Moraczewski et al., 2009), 
and various corneal pathologies (Dastjerdi et al., 2009; Jacobs 
et al., 2009; Oh et al., 2009). To date, the benefit of this ther-
apy for AMD patients is, at best, transient, although its pro-
longed use for up to 7 mo has no deleterious effects on the 
retina or choroids (Ueno et al., 2008). Bevacizumab was also 
the first FDA-approved angiogenesis inhibitor mAb for treat-
ment of metastatic colorectal, nonsmall cell lung, and breast 
cancers  in  combination  with  conventional  chemotherapy 
(Salgaller, 2003; Gerber and Ferrara, 2005; Reichert and 
Valge-Archer, 2007; Ellis and Hicklin, 2008; Ma and Adjei, 
2009). After a period of clinical benefit, however, this mAb 
fails to produce an enduring clinical response in most patients 
as a result of adaptive resistance and compensatory mecha-
nisms (Dorrell et al., 2007; Bergers and Hanahan, 2008). An-
other important limitation of this drug is that it also affects 
the vasculature of normal tissues leading to diverse adverse 
effects including risk of arterial thromboembolic events (Ratner, 
2004; Chen and Cleck, 2009).
Given the evidence that resistance develops to anti-VEGF 
mAb therapies, there is a pressing need to develop additional 
and/or combined antiangiogenic therapies that inhibit path-
ological neovascularization while having little or no effect on 
normal  mature  tissue  vasculature.  We  hypothesized  that 
CD160, a glycosylphosphatidylinositol-anchored protein ini-
tially known as BY55 (Bensussan, 2000), might be an interest-
ing antiangiogenic target in vivo for the following reasons. 
First, the distribution of CD160 in healthy tissues in situ is JEM VOL. 208, May 9, 2011 
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parameters for accurately evaluating any retinal antiangio-
genic effect. Intravitreal injection of  CL1-R2 significantly 
decreased (35%) the mean number of endothelial cell nu-
clei per section in both ganglion cell and inner nuclear layers 
as compared with animals injected with control IgG1 (P < 
0.001; Fig. 2 D). Furthermore, CL1-R2 reduced the mean 
number of vessel lumens per section by 50% when com-
pared with mock-treated (P < 0.001) or IgG1-treated control 
mice (P < 0.001), respectively (Fig. 2 E). We then compared 
the effect of CL1-R2 treatment to that of the widely used 
mAb bevacizumab in the same mouse model regardless of the 
controversy dealing with the specificity of bevacizumab to 
neutralize murine VEGF-A (Yu et al., 2008). Several studies 
have indeed conclusively demonstrated that bevacizumab, de-
spite its weak affinity for the VEGF-A produced by mice, rats, 
guinea pigs, and rabbits, is efficient in treating experimentally 
induced corneal neovascularization in these animals (Bock   
et al., 2007; Manzano et al., 2007; Hurmeric et al., 2008; 
Hashemian et al., 2009; Habot-Wilner et al., 2010). Further-
more, a recent study showed unambiguously that bevacizumab 
had a very significant inhibitory effect on retinal angiogenesis 
in the oxygen-induced retinopathy mouse model (Zhang 
et al., 2009). These latter results are in full agreement with 
ours. After intraocular injection of bevacizumab, we observed 
normalized retinal vascularization on flat-mounted retinas 
and retinal tissue sections comparable to that obtained after 
CL1-R2 treatment (Fig. S2, A and B). Quantitative analysis 
indicated that the mean number of endothelial cell nuclei 
per section was not significantly different between CL1-R2–
treated and bevacizumab-treated mice (Fig. S2 C), whereas 
the number of vessel lumens per section was significantly 
lower in CL1-R2–injected mice than in bevacizumab-treated 
control mice (P < 0.05; Fig. S2 D). Overall, these data show 
that CL1-R2 mAb monotherapy efficiently suppresses path-
ological angiogenesis in rabbit cornea and mice with isch-
emic retinopathy.
The CL1-R2 mAb inhibits FGF2-induced vascularization  
in the mouse Matrigel plug assay
We then evaluated the antiangiogenic effect of CL1-R2 in 
vivo on the mouse Matrigel plug model of angiogenesis 
(Passaniti et al., 1992). This assay, in which Matrigel plugs 
containing FGF2 are injected subcutaneously into mouse flanks, 
has proven to be a relatively easy method to evaluate anti-
angiogenic compounds in vivo. Initial indications of the lev-
els of activity of antiangiogenic compounds can be assessed 
visually because of the color difference in the vascularized 
plugs when compared with the controls. The pale color of the 
plugs removed from CL1-R2–treated mice indicated little 
FGF2-induced vascularization over a 7-d period (Fig. 3 A, 
top). In contrast, the reddish color of the plugs in the control 
IgG1-treated mice reflected the development of dense neo-
vascularization. We next compared the vessel density in CL1-
R2–treated and control Matrigel plugs sections stained with 
the endothelial cell-specific marker isolectin B4. Representative 
sections are shown (Fig. 3 A, bottom). The vessels in plugs from 
in the superficial retinal layer and a polygonal reticular pattern 
in the deep retinal layer. Retinas from oxygen-treated animals 
with no intraocular injection (Fig. 2 A, Mock) or intraocular 
injection of control IgG1 (Fig. 2 A, Ctrl) displayed neovascu-
lar tufts that released fluorescein and had tortuous radial vessels 
and a central avascular zone, which is consistent with previ-
ous descriptions of this model. After intraocular injection of   
CL1-R2, avascular areas decreased in size and the retinas con-
tained fewer neovascular tufts and fewer tortuous and dilated 
radial vessels (Fig. 2 A), suggesting better perfusion efficiency 
in the central vessels.
Eyes from the various untreated or oxygen-treated ani-
mals were analyzed further by histology. Serial ocular tissue 
sections were stained with periodic acid–Schiff reagent to   
visualize the nuclei of endothelial cells (Fig. 2 B). Unlike the 
retinas from mice in a normoxic environment (normal retina), 
the retinas of mock-treated mice typically contained abun-
dant longitudinal and transverse aberrant microvessels of 
various sizes in the vitreous space and inner retina, as well as 
endothelial cell nuclei identified by periodic acid–Schiff  
staining (Fig. 2 B). Retinas from control IgG-treated animals 
displayed similar neovascularization with abundant aberrant 
microvessels and endothelial cell nuclei (Fig. 2 B). In contrast, 
retinas from mice injected with CL1-R2 had significantly 
fewer aberrant vessels, which were greatly reduced in size,   
especially in the vitreous space and within the retina, and fewer 
endothelial cell nuclei. Von Willebrand factor staining further 
confirmed that periodic acid–Schiff-positive cells were endo-
thelial cells (Fig. 2 C). To quantify retinal neovascularization, 
endothelial cell nuclei and lumens of neovessels were counted 
in a large number of samples before and after the administration 
of CL1-R2 or control IgG1 (Fig. 2, D and E). These are crucial 
Figure 1.  CL1-R2 inhibits FGF2-induced rabbit corneal neoangio-
genesis. (A) Representative photographs of corneas treated with control 
IgG1 (Ctrl) or CL1-R2 mAb. Neovascularization was assessed 8 d after 
corneal grafting of FGF2-containing implants. Arrows, implants; arrow-
head, neovessels. Bar, 2 mm. (B) Quantitative analysis of neovasculariza-
tion in Ctrl- or CL1-R2–treated corneas. Values are means ± SEM obtained 
from four independent experiments, n = 5 rabbits/group/experiment.  
***, P < 0.0001 (Mann-Whitney U test).976 Antiangiogenic therapy targeted to CD160 | Chabot et al.
Figure 2.  Intravitreal injection of CL1-R2 reduces retinal neovascularization in a murine model of oxygen-induced retinopathy. Retinal 
neovascularization was induced by exposing 7-d-old mice to 75 ± 2% oxygen for 5 d, and then to normoxia. Animals were injected intravitreally with 
control IgG1 or CL1-R2 or received no injection. (A) Flat-mounted retinas harvested from 17-d-old pups were perfused with FITC-dextran and observed 
by fluorescence microscopy to assess retinal vasculature. Representative flat-mounted retinas are from normal mice (Normal retina), mice exposed to 
hyperoxic conditions without injection (Mock), or mice injected intravitreally with 5 µg IgG1 (Ctrl) or 5 µg CL1-R2. Central avascular zone, arrowheads; 
neovascular tufts, asterisks. Data are representative of three independent experiments (n = 6–11 mice/group). Bars: (top) 770 µm; (bottom) 335 µm.  
(B) Histological analyses (periodic acid–Schiff staining) of whole eye tissue sections. Representative photomicrographs of eye sections from normal 
mice (Normal retina; n = 3) and mice exposed to hyperoxic conditions without injection (Mock; n = 6) or injected intravitreally with IgG1 (Ctrl; n = 9) or 
CL1-R2 (n = 11). Longitudinal and transverse aberrant microvessels, arrows; isolated nuclei of endothelial cells not involved in tube formation, asterisks. 
GCL, ganglion cell layer; INL, inner nuclear layer. Bar, 50 µm. (C) Von Willebrand Factor staining of whole eye tissue sections. Representative photomicro-
graphs of eye sections from normal mice (Normal retina) and mice exposed to hyperoxic conditions without injection (Mock) or injected intravitreally 
with IgG1 (Ctrl) or CL1-R2 mAb. After paraffin removal, sections were rehydrated, treated with 0.3% Triton X-100, and incubated with polyclonal anti-
body against Von Willebrand factor, followed by Alexa Fluor 488 secondary antibody (green) and counterstaining with DAPI (blue). GCL, ganglion cell 
layer; INL, inner nuclear layer. Bar, 25 µm. (D and E). Quantitative assessment of the retinal vascularization illustrated in B for 6 (Mock), 9 (Ctrl), or 11 
(CL1-R2) mice/group. Endothelial cell nuclei and vessel lumens were counted on four to eight sections per eye stained with periodic acid–Schiff  
reagent. The mean number of endothelial cell (EC) nuclei (D) and vessel lumen (E) presented in the histograms were determined using a Poisson regression 
model for clustered data. 95% confidence intervals of the mean number estimates are figured as error bars. P-values were corrected for post-hoc group 
comparisons by the Bonferroni method. **, P < 0.001.JEM VOL. 208, May 9, 2011 
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which  is  poorly  immunogenic  and  highly  vascularized. 
Histological analysis of these tumors showed that the vascu-
larization was significantly lower in CL1-R2–treated mice 
than in control animals (Fig. 4, A and B; P = 0.0001). His-
tology gave an instantaneous picture of vascularization but 
did not reflect the functionality of blood vessels. So we used 
another approach based on the use of color Doppler ultraso-
nography (DUS), a noninvasive method of visualizing tumor 
vessels in situ at different times (Asselin-Paturel et al., 1999). 
DUS demonstrated that the vascular density of B16 tumors at 
12, 15, and 18 d after CL1-R2 injections was significantly 
lower than that of tumors in control mice that received IgG1 
injections (Fig. 4, C and D; and  Videos 1 and 2). As B16 tumor 
cells are sensitive to cyclophosphamide (Hamano et al., 2004), 
we also investigated whether the observed vascular changes 
after CL1-R2 treatment increased susceptibility to this cyto-
toxic agent. The combination of both mAb and chemothera-
peutic agent, administered according to a metronomic schedule, 
significantly reduced the growth of B16 tumor (Fig. 4 E; P = 
0.0001) compared with control IgG1 with cyclophosphamide. 
Thus, CL1-R2 and cyclophosphamide act in concert to re-
duce neovascularization and slow the growth of B16 tumor.
Treatment with the CL1-R2 mAb normalizes the remaining 
vasculature of B16 tumors
The normalization of tumor vasculature with antiangiogenic 
therapy is an emerging concept (Jain, 2005). This vascular 
normalization implies that any antiangiogenic strategy should 
target immature dysfunctional vessels and fortify those remain-
ing. To investigate the effect of CL1-R2 on tumor normal-
ization, we used intravital microscopy. This method allows 
the continuous noninvasive analysis of the same tumor area in 
its orthotopic environment (in a dorsal skin-fold chamber) 
over a 2-wk period, including measurement of blood flow–
related variables such as vessel diameter, microvascular density, 
and branching (Jain et al., 2002; Koehl et al., 2009). Wide-
field intravital fluorescence microscopy showed that CL1-R2 
injections  together  with  cyclophosphamide  significantly  re-
duced B16 tumor growth over a 14-d period after tumor im-
plantation when compared with IgG1-treated control mice 
with cyclophosphamide (not depicted), confirming results 
obtained by caliper measurements (Fig. 4 E). The first signs 
of angiogenesis, including dilation and tortuous elongation of 
preexisting blood vessels, were observed in the host tissues of 
control mice soon after melanoma implantation (Fig. 5, A and B). 
This phenomenon was a result of the proliferating tumor   
remodeling the host vessels, as no modification of the pre-
existing vessels was observed in the absence of a grafted tumor 
(Fig. S3). Treatment of mice with CL1-R2 limited host vessel 
dilation and tortuosity (Fig. 5 A and Fig. S4). The B16 tumors 
were  vascularized  over  a  substantial  area  in  control  mice, 
whereas the area of tumor vascularization was much smaller 
in CL1-R2–treated animals 12 d after implantation (Fig. 5 B). 
At day 14 after tumor implantation (the last day of the experi-
ment), the vascular area of B16 tumors in CL1-R2–treated 
mice was 2.56-fold smaller than in control mice (Fig. 5 B). 
CL1-R2–treated animals were smaller and fewer in number 
than those in plugs from the control mice. We quantified the 
level of angiogenesis by determining the hemoglobin content 
of the plugs and found a marked reduction (45%, P = 0.0153) 
in plugs from CL1-R2–treated mice when compared with 
those from IgG1-treated control mice (Fig. 3 B). In 14 out of 
22 CL1-R2–treated Matrigel plugs, the hemoglobin content 
was extremely low. These data indicate that the CL1-R2 mAb 
significantly impaired angiogenesis in this in vivo assay.
Treatment with the CL1-R2 mAb inhibits transplanted 
murine B16 vascular density
To further evaluate the antiangiogenic activity of CL1-R2 in vivo, 
we used the transplanted mouse B16 melanoma tumor model, 
Figure 3.  CL1-R2 inhibits FGF2-induced neoangiogenesis in a 
Matrigel plug model. (A, Top) Photographs of representative FGF2- 
containing Matrigel plugs taken from control IgG1- and CL1-R2–treated 
mice 7 d after plug implantation. (A, Bottom) Representative sections of 
FGF2-containing Matrigel plugs taken from control IgG1- and CL1-R2–
treated mice on day 7. Endothelial cells were labeled with isolectin B4 
(brown) and the sections were counterstained with hematoxylin (blue). 
Arrowheads indicate isolectin B4-positive vessels. Bar, 50 µm. Representative 
images of five independent experiments. (B) Quantification of hemoglobin 
in FGF2-containing Matrigel plugs removed from control IgG1- and CL1-R2–
treated mice. Horizontal bars represent the mean hemoglobin content. n = 11 
IgG1-treated mice; n = 22 CL1-R2–treated mice. *, P = 0.0153 (Mann-
Whitney U test). Pooled data are from five independent experiments.978 Antiangiogenic therapy targeted to CD160 | Chabot et al.
remaining tumor vasculature when compared with IgG1-
treated mice. Moreover, our data indicate that CL1-R2 treat-
ment was effective not only if the mAb was injected on the 
same day as tumor cell implantation but also if injected 3 d 
after tumor inoculation (Fig. 4, C and D) or if a B16 tumor 
fragment was implanted under the skin (Fig. 5).
B16 tumor vasculature in CL1-R2–treated mice is mature 
and functional for chemotherapeutic drug delivery
Tumor blood vessels are immature and display functional de-
fects, including vessel lumen collapse leading to restricted 
blood flow and poor access to the chemotherapeutic agents 
(Carmeliet, 2005; Jain, 2005; Hamzah et al., 2008). Open lu-
mens are thus a good indicator of vessel maturation and func-
tionality in solid tumors. By counting the vessels in different 
fields of each tumor section, we found that a greater proportion 
of B16 tumor vessels had an open lumen in CL1-R2–treated 
mice than in control animals (Fig. 6 A). Pericytes recruited 
We then performed a fractal analysis to quantify the geomet-
ric complexity of the vascular network. This analysis offers an 
additional method for measuring tumor vascular damage 
given that tumor vasculature is characterized by loss of hier-
archical architecture (Heymans et al., 2000). We found that 
the B16 tumor vasculature in CL1-R2–treated mice had a 
significantly smaller fractal dimension than in control mice 
(Fig. 5 C). These results indicate that treatment with CL1-R2 
favored a better hierarchical architecture of the B16 tumor 
vessel network, which may influence the circulation. Consis-
tent with this finding, B16 tumor vessel diameters in IgG1-
treated mice varied from 2.35 to 48.33 µm, in contrast to the 
much  more  uniform  tumor  vessel  diameters  observed  in 
CL1-R2–treated animals (6.46 to 25.94 µm; Fig. 5 D). Col-
lectively, these observations, based on a wide range of vascular 
parameters, indicate that the CL1-R2 mAb, combined with 
cyclophosphamide chemotherapy, results in a reduced vascular 
density in transplanted B16 tumors and normalization of the 
Figure 4.  Diminished vascular density of 
B16 melanoma tumors in CL1-R2–treated 
mice. (A) Immunohistochemical assessment of 
vascular density in B16 tumor sections taken 
on day 16 from mice treated with control IgG1 
(Ctrl) or CL1-R2, both in combination with 
cyclophosphamide (CycloP). Endothelial cells 
in representative sections were stained with 
isolectin B4 (brown) and counterstained with 
hematoxylin (blue). Images are representative 
of five mice in each group. Bar, 50 µm. 
 (B) Quantification of the data shown in A. 
Vessel density was counted in four indepen-
dent areas on each B16 tumor section. ***, P < 
0.0001 (one-way ANOVA test). Error bars rep-
resent SEM. (C) 3 d after B16 cell injection, 
mice received repeated i.p. injections of CL1-
R2 or IgG1 (Ctrl). Cyclophosphamide was then 
added to the drinking water. Mice were exam-
ined by DUS to identify intratumoral blood 
vessels 12, 15, and 18 d after the first CL1-R2 
injection. Power Doppler mode color DUS ul-
trasound images with intratumoral blood ves-
sel signals are shown in red/yellow. 
Representative images obtained from the 
same tumor cross section in a single mouse 
from day 12 to 18 are shown for each treat-
ment. Bar, 5 mm. Side bar: Doppler power, 
maximum 4.3. (D) Quantification of the num-
ber of intratumoral vessels in IgG1-treated 
(black bars) and CL1-R2–treated (gray bars) 
mice determined from multiple cross sections 
of the tumor. Tumor vessel number on the 
ordinate represents the mean number of total 
intratumoral blood vessels per tumor because 
the whole tumor was scanned at each time 
point for the detection of blood vessels. Data are 
expressed as means ± SEM (n = 5 mice in each 
group). *, P = 0.0203 for day 12; **, P = 0.0032 for day 15; **, P = 0.0077 for day 18 (Student’s t test). (E) B16 tumor growth in untreated (PBS), CL1-R2–treated 
(500 µg, three times a week), or control mice in combination with cyclophosphamide treatment. Tumor volumes were measured at the indicated times after tumor 
inoculation. Data from four experiments (n = 5 mice/group) were pooled. Data represent mean tumor size values ± SEM. ***, P < 0.0001 (two-way ANOVA test).JEM VOL. 208, May 9, 2011 
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vessels. Little perivascular labeling was 
observed  in  B16  tumor  vessels  from 
control mice despite a high level of vas-
cularization (Fig. 6 C). In contrast, most 
of the tumor vessels in CL1-R2–treated mice displayed in-
tense perivascular staining. Thus, treatment with CL1-R2 im-
proved perfusion efficiency in B16 tumor vessels. We next 
evaluated the extent to which CL1-R2 influenced tumor 
necrosis as a result of cyclophosphamide. Histological studies 
showed more extensive necrosis in CL1-R2–treated tumors 
than in controls (Fig. 6 D), suggesting that CL1-R2 treatment 
improved the delivery of cyclophosphamide by normalizing 
the remaining tumor blood vessels. Together, these findings 
demonstrated that CL1-R2 mAb treatment not only reduced 
abnormal tumor vasculature but also favored the maturation 
and function of the remaining tumor vessels.
To evaluate the therapeutic benefit of CL1-R2 mAb in-
jection and to make a comparison with anti-VEGF mAb 
along endothelial cells are another indicator of maturation 
and normal functioning of blood vessels (Carmeliet, 2005). 
We therefore evaluated the pericyte coverage of B16 tumor 
vessels by confocal microscopy. The vasculature of tumors from 
CL1-R2–treated mice exhibited strong staining for smooth 
muscle actin (SMA; a marker of pericytes), unlike tumor vessels 
from control mice which displayed little or no staining for 
SMA (Fig. 6 B). These data suggested that CL1-R2–treated 
tumor vessels might have a lower resistance to blood flow, 
which may improve the blood supply within the tumor. To eval-
uate blood perfusion, Hoechst 33342 fluorescent dye was ad-
ministered intravenously and its uptake by tumor vessels was 
examined by fluorescence microscopy. This dye labels the nuclei 
of endothelial cells and cells adjacent to the walls of perfused   
Figure 5.  Normalization of B16-GFP mela-
noma tumor vessels in CL1-R2–treated mice 
observed by in vivo intravital fluorescence 
microscopy. (A, Left) Host vessels surrounding 
the tumor in control Ig or CL1-R2–treated mice 
in combination with cyclophosphamide at day 9 
after tumor implantation. Contrast was en-
hanced by i.v injection of 150 kD TRITC-labeled 
dextran. Arrowheads and arrows point to the 
same tumor vessels at day 0 (d0) and day 9 (d9), 
respectively. Bars, 40 µm. (A, Right) Quantifica-
tion of the data in the left panel. Data represent 
mean values ± SEM (n = 5 mice/group). ***, P < 
0.0001 (two-way ANOVA test). (B, Left) Tumor 
vascular area 12 or 14 d after CL1-R2 treatment 
or control IgG1. Bars, 40 µm. (B, Right) Quantifi-
cation of the tumor vascular areas in the left 
panels. Values are means ± SEM (n = 5 mice/
group). *, P = 0.0114 (day 12); *, P = 0.0292 (day 
14; Student’s t test). (C, Left) Intratumoral mi-
crovasculature in day-14 control IgG1- or CL1-
R2–treated mice. Bars, 40 µm. (C, Right) 
Quantitative analysis of vascular network com-
plexity based on microvessel fractal dimension 
measurements in IgG1-treated (Ctrl) and CL1-
R2–treated mice. Values are means ± SEM (n = 5 
mice/group). *, P = 0.0211 (Student’s t test).  
(D, Left) Microangiography of IgG1-treated 
(Ctrl) and CL1-R2–treated tumors on day 14 
after implantation. Bars, 40 µm. (D, Right) 
Quantitative data from a representative experi-
ment (plotted in the box/whisker format) com-
paring IgG1-treated (Ctrl) and CL1-R2–treated 
tumors on day 14 after implantation (n = 5 
mice/group). Box plots show median values 
(horizontal line inside the whiskers box), box 
boundaries represent quartiles, and error bars 
represent the lowest and highest values. Images 
and quantitative data are representative of 
three independent experiments.980 Antiangiogenic therapy targeted to CD160 | Chabot et al.
human healthy colon and colon tumors. 
The  vessels  present  in  colon  tumors 
were strongly stained by CL1-R2 with 
patterns resembling those stained for CD31, a human endo-
thelial cell marker (Fig. 7 B). In contrast, CL1-R2 did not 
stain the blood vessels present in healthy colon. As CL1-R2 
recognized newly formed vessels in solid tumors but not ves-
sels from healthy tissues, its therapeutic antiangiogenic effect 
is likely to be restricted to these neovessels.
DISCUSSION
Overall, our findings show that in monotherapy CL1-R2 mAb 
efficiently blocks pathological angiogenesis in both rabbit cor-
nea and mice with ischemic retinopathy, whereas in combined 
therapy it restricts the development of abnormal B16 tumor 
(bevacizumab), we compared the B16 tumor burden after these 
different treatments combined with cyclophosphamide (Fig. S5). 
CL1-R2 mAb injection improved the mouse survival (35 d), 
compared with the earlier death (30 d) of mice injected 
with bevacizumab (P = 0.032) or control IgG1 (P = 0.016).
We investigated further whether CL1-R2 specifically tar-
geted CD160 expressed by B16 tumor vessels. A representa-
tive section of B16 tumor showed intense staining of CD160 
similar to that of the isolectin B4 endothelial marker (Fig. 7 A). 
In contrast, CD160 was barely detectable in the vessels of 
normal mouse heart in comparison with the strong isolectin 
B4 staining. We also evaluated the distribution of CD160 in 
Figure 6.  The B16 tumor vasculature in 
CL1-R2–treated mice is mature and func-
tional. All data presented were obtained from 
mice 16 d after tumor implantation (A, Left) 
Representative B16 tumor vessels stained with 
isolectin B4 (brown staining; counterstaining, 
hematoxylin) from mice treated with CL1-R2 or 
control Ig in combination with cyclophospha-
mide. Bar, 50 µm. (A, Right) Histogram showing 
the number of vessels with an open lumen. 
Number of fields: four. n = 5 mice per group.  
*, P = 0.0341 (Student’s t test). (B, Left) CD34-
positive endothelial cells (green) are covered by 
SMA (red) pericyte cells in B16 tumors from 
CL1-R2–treated mice (bottom) compared with 
IgG1-treated Ctrl mice (top). Nuclei are labeled 
blue. Images were taken with confocal fluores-
cence microscopy. Bar, 20 µm. (B, Right) Quan-
tification of the number of endothelial cells 
covered by pericytes. The ratio of total area red 
staining (SMA) to green staining (CD34) was 
calculated (10 fields per tumor, 5 tumors). Val-
ues are means ± SEM. ***, P < 0.0001. (C, Left) 
Cryosections of B16 tumors from control and 
CL1-R2–treated mice stained with isolectin B4 
(red). Hoechst staining (blue) indicates perfused 
vessels. Insets show images at higher magnifi-
cation. Bars, 50 µm. (C, Right) Quantification.  
n = 5. Number of fields: 4. **, P = 0.0047 (un-
paired Student’s t test with Welch’s correction). 
Control = 24.59 ± 7.086 (n = 5); CL1-R2 = 
65.52 ± 1.158 (n = 5). (D, Left) Histopathology 
of B16 tumors stained with hematoxylin and 
eosin. Necrosis is indicated by arrowheads.  
Bar, 200 µm. (D, Right) Quantification of ne-
crotic areas in B16 tumors from CL1-R2–
treated and control mice. n = 5 mice/group. 
Number of fields: 4. **, P = 0.0092 (Student’s t 
test with Welch’s correction). Images and quan-
titative data are representative of three inde-
pendent experiments. The data in A, C, and D 
are means ± SEM of four different microscope 
fields for each tumor and a total of five different 
tumors in each treatment group.JEM VOL. 208, May 9, 2011 
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the CL1-R2–mediated inhibition of in vivo ocular and cancer 
neoangiogenesis described in this paper is the consequence of 
a similar caspase-dependent apoptosis mechanism. Such a 
mechanism differs from the existing antiangiogenic therapies 
targeted to VEGF/VEGFR and thus may be useful when re-
sistance to these latter therapies occurs. We cannot exclude 
the possibility of a synergic antiangiogenic effect caused by 
both cyclophosphamide and the CL1-R2 mAb, as chemo-
therapeutic drugs administered with a metronomic schedule 
have been reported to display antiangiogenic properties (Man 
et al., 2002). However, this is unlikely in the B16 melanoma 
tumor model, as cyclophosphamide treatment alone had no 
effect on tumor vascular density, suggesting that CL1-R2 
might be solely responsible for the antiangiogenic effect ob-
served when combined with cyclophosphamide.
In addition to its antiangiogenic effect, we demonstrated 
that CL1-R2 mAb contributes to the normalization of re-
maining B16 vessels by producing unbranched vessels with 
homogeneous diameters and open lumens, resulting in a bet-
ter organized network similar to the vasculature of normal 
tissues. Importantly, CL1-R2 treatment strongly increased the 
association of pericytes with the B16 tumor vasculature, dem-
onstrating their mature status. Consistent with this, we observed 
in a transplant model of ALK-induced fibroblast tumors in 
athymic nude mice (Giuriato et al., 2007), treated with CL1-
R2 mAb alone (without any combined chemotherapy), that 
the tumor vessels had a mature phenotype, i.e., open lumen 
and pericyte coverage, which is in contrast with cyclophos-
phamide monotherapy (Fig. S6). These latter observations 
made in a second tumor model confirm that CL1-R2 has   
a direct effect on the maturation of tumor vascularization. 
This property is important, as it has been shown that anti-
VEGF therapy inhibited tumor vessel maturation and peri-
cyte  function  (Greenberg  et  al.,  2008).  Mature  vessels  are 
more resistant to the pressure exerted by proliferating tumors, 
favoring drug delivery within the tumor (Padera et al., 2004). 
This should be the case for B16 tumors treated with CL1-R2 
mAb, as we observed extensive intratumor necrosis. Moreover,   
it has been recently shown that the level of vessel maturation 
significantly contributed to the response toward antiangiogenic 
therapy in melanoma (Helfrich et al., 2010). Thus, CL1-R2 
induced normalization of B16 tumor vessels, leading to the 
establishment of a stable and functional vessel network. It was 
shown that antiangiogenic drugs could generate a normaliza-
tion window for improved delivery of chemotherapeutic drugs 
(Lin and Sessa, 2004). Because we gave cyclophosphamide at the 
same time as CL1-R2 mAb, i.e., from day 0 of B16 tumor im-
plantation, it is very unlikely that a normalization window oc-
curred in our tumor model. For the same reason, it is also unlikely 
that B16 tumors acquired an invasive and metastatic phenotype 
after CL1-R2 treatment, as has been recently described in other 
mouse tumor models (Pàez-Ribes et al., 2009). Normalization 
by CL1-R2 treatment of retinal vascularization in mice with 
ischemic retinopathy was also observed by ex vivo angiogra-
phy (Fig. 2 A). These results suggest that the antiangiogenic 
and normalization effects are not mutually exclusive.
vasculature and normalizes the remaining vessels, allowing a 
better delivery of a cytotoxic agent. Although CL1-R2 ther-
apy could be used with combined angiostatic drugs that in-
hibit other parts of the angiogenic process (Dorrell et al., 2007; 
Takeda et al., 2009), our data suggest that CL1-R2 might be ef-
fective as a monotherapy for several human ocular diseases as-
sociated with neovascularization, such as diabetic retinopathy 
and AMD with choroidal neovascularization. These diseases 
remain a major cause of blindness and poor vision worldwide 
with an expected doubling of the prevalence of AMD in the 
coming decades as a result of the projected increase in the 
aging population.
We have previously demonstrated that, in vitro, CL1-R2 
mAb inhibited FGF2-mediated tubule vessel growth from 
human  umbilical  vein  endothelial  cells  expressing  CD160 
and induced their apoptosis (Fons et al., 2006). It is likely that 
Figure 7.  Expression of CD160 in tumor blood vessels but not in 
the blood vessels of healthy tissues. (A) Representative sections of B16 
melanoma at day 16 after their subcutaneous injection (top) and healthy 
mouse heart (bottom), both stained with either CL1-R2 (CD160) or isolec-
tin B4, an endothelial cell marker. Bar, 50 µm. Images are representative of 
four independent experiments (five mice/group). (B) Sections of human 
colon tumor (top) and healthy colon (bottom) stained with CL1-R2 
(CD160) or a mAb against CD31, a human endothelial cell marker. Images 
are representative of two patient biopsies. Control IgG1 did not stain and 
is not shown. Bar, 50 µm.982 Antiangiogenic therapy targeted to CD160 | Chabot et al.
blotting, we found that the CNX46-3 anti–mouse CD160 mAb (Cedarlane 
laboratories) immunoprecipitated protein bands from mouse spleen or 
BCL-1 cells that were blotted by the CL1-R2 mAb (Fig. S1 B); and (3) five 
CD160 amino acids were identified by mass spectrometry in the CNX43-6–
immunoprecipitated 37-kD band blotted with CL1-R2 mAb with a mini-
mum coverage of 37.5% (Fig. S1 C).
Animals. We used BALB/c, C57BL/6J, and NMRI-nu (nu/nu) Nude mice 
(Janvier Laboratories). Mice were 7–10 wk old, except for those used for the 
ischemic retinopathy experiments which were 7 d old. Animals were housed 
in a conventional temperature-controlled room (21°C), exposed to a daily 12-h 
period of light and dark, and fed ad libitum with a balanced diet as deter-
mined by The Jackson Laboratory for the C57BL6/J mouse strain. We used 
male New Zealand albino rabbits from Institut National de la Recherche 
Agronomique (Castanet-Tolosan). For the mouse retina experiments, animals 
were handled according to the guidelines of the institutional animal care com-
mittee, using protocols approved by the Ethics Committee and the ARVO 
Statement for use of Animals in Ophthalmic and Vision Research. All other 
animal experiments were performed in agreement with the European Union 
guidelines and the Midi-Pyrénées Ethic Committee for the care and use of 
laboratory animals (MP/02/37/06/08).
In vivo rabbit corneal angiogenesis assay. The corneal pocket assay used 
in this study has been previously described (Fons et al., 2006). We made an 
incision in the upper side of the cornea, 2 mm from the limbus in anesthe-
tized rabbits. FGF2-treated implants (500 ng; R&D Systems) were inserted 
into this pocket. Subconjunctival injections of CL1-R2 mAb or control 
IgG1 (100 µg in 30 µl PBS) were administered to the upper side of the limbus 
24 and 72 h after corneal implantation. Corneal neovascularization was mea-
sured 8 d after implantation and was scored on a four-grade scale based on 
the length of the newly formed vessels from the limbus to the FGF2-containing 
implant (Fons et al., 2006).
Murine model of oxygen-induced retinopathy and intravitreal injec-
tions. Retinal neovascularization was induced in mouse C57BL/6J pups   
using a well established and reproducible model of oxygen-induced retinopa-
thy (Smith et al., 1994). In brief, mice (7 d old, P7) and their nursing mothers 
were placed in an airtight incubator and exposed to a 75 ± 2% oxygen atmo-
sphere for 5 d. The oxygen level was continuously monitored with an oxygen 
analyzer (model 110; PROOX; BioSpherix). Mice were removed on P12 and 
maintained in normoxic conditions (room air) until P17. Mice were injected 
intravitreally under an operating microscope. With the exception of the non-
injected group, each pup received an intravitreal injection in their left and 
right eyes on P12. In brief, mouse pups were anesthetized with an intramus-
cular injection of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg 
body weight). The palpebral fissures were opened with microscissors and pu-
pils were dilated with topical 10% phenylephrine and 0.5% tropicamide. The 
tip of a 10-mm 33-gauge steel needle, mounted on a 5-µl Hamilton syringe, 
was pushed through the sclera, 1 mm posterior to the corneoscleral limbus, 
into the vitreous body. Approximately 1 µl CL1-R2 mAb (5 µg/µl), bevaci-
zumab (25 µg/µl; Roche), or IgG1 isotype control mAb (5 µg/µl) was in-
jected into the vitreous cavity.
Qualitative and quantitative assessment of retinal neovascularization. 
Mice were killed at P17 to analyze neovascularization by histology and quan-
titative measurements. Some mice underwent retinal angiography with 
fluorescein-dextran. For this qualitative assessment, we anesthetized mouse 
pups as previously described and perfused the heart through the left ventricle 
with 1 ml PBS containing 50 mg/ml fluorescein-labeled dextran (2 × 106 mean 
molecular weight; Sigma-Aldrich) that had been cleared by centrifugation for 
5 min at 10,000 rpm. The eyes were enucleated and fixed in 4% paraformalde-
hyde for 3 h. The cornea and lens were removed and the retina was dissected 
from the eyecup. The retina was cut into four quadrants and flat mounted 
in Vectashield under a coverslip for examination by fluorescence microscopy. 
At least 12 eyes from each treatment were examined. For the histological analysis, 
CL1-R2 is a bifunctional mAb, as it blocks neoangiogen-
esis, normalizing the remaining tumor vessels (this study), but 
may also activate the innate immune system (Le Bouteiller et al., 
2002; Barakonyi et al., 2004). Although we did not investigate 
whether CL1-R2 mAb therapy activated NK cells, this possi-
bility cannot be excluded as we previously demonstrated that 
specific binding of CL1-R2 mAb to CD160 on human pe-
ripheral blood NK cells triggered interferon-, TNF, and IL-6 
production, which participated in the inflammatory response 
(Barakonyi et al., 2004). Activation of NK cells by CL1-R2 
may thus contribute to slowing tumor growth in addition to 
the antiangiogenic and normalization effects of the mAb. In 
contrast, in cornea or retina such CL1-R2–mediated NK cell 
activation is unlikely, as these cells are generally not present in 
these tissues (Ambati et al., 2006).
In summary, we have demonstrated that the CL1-R2 mAb 
exerts an antiangiogenic effect on tumors in vivo; by normal-
izing the vasculature, it thus improves perfusion and enhances 
the accessibility of the tumor to chemotherapeutic drugs. These 
studies indicate that targeting the CD160 receptor with a spe-
cific mAb, CL1-R2, is a promising therapeutic option that 
could be used in monotherapy or combination therapy for 
the treatment of many diseases with associated pathological 
neovascularization. The spectrum of neovascular diseases that 
could be treated is potentially large, including several vision-
threatening eye diseases and many solid tumors associated 
with high levels of angiogenesis. CL1-R2 monotherapy might 
be particularly apt for treatment of ocular neovascular diseases 
in humans, as this mAb has antiangiogenic activity alone in 
animal models of both corneal and retina neoangiogenesis.   
In combination with intravenous chemotherapy, CL1-R2 might 
be useful for highly vascularized cancers as this mAb also trig-
gers vessel normalization, opening the way to a successful 
chemotherapy. Further investigations are ongoing to ascertain 
the appropriate CL1-R2 mAb dosing regimens, best route of 
delivery, and duration of therapy to manage the toxicities and 
risks of systemic exposure and to select the most effective 
humanized mAbs with the lowest level of immunogenicity 
that may be successful for treating ocular neovascular diseases 
and cancer (Cao and Langer, 2010).
MATERIALS AND METHODS
Murine anti–human CD160 CL1-R2 mAb. The mouse anti-CD160 
CL1-R2 mAb (IgG1) was developed in our laboratory and was evaluated as 
an anti-CD160 mAb during the seventh Human Leukocyte Differentiation 
Antigen Workshop (Bensussan, 2000). We produced the CL1-R2 mAb from 
a specific secreting hybridoma cell line by using the high cell density system 
CELLine (Valdea Biosciences). The endotoxin unit concentration was <0.6 
EU/mg of IgG. The mouse IgG1 isotype control monoclonal antibody He6 
was developed by immunizing mice with hepatitis B surface antigen. Both 
CL1-R2 and IgG1 isotype control were similarly purified by affinity chro-
matography on a HiTrap protein G column (GE Healthcare) in an ÄKTA 
purifier system (GE Healthcare), dialyzed against PBS, pH 7.0, concentrated, 
and filtered through 0.22-µm filters. The cross-reactivity of CL1-R2 mAb 
with CD160 mouse proteins has been demonstrated by different means 
(Fig. S1): (1) using flow cytometry, we found that CL1-R2 stained mouse 
SVR endothelial cells as well as the BCL-1 mouse B cell chronic lympho-
cytic leukemia cell line (Fig. S1 A); (2) using immunoprecipitation and Western JEM VOL. 208, May 9, 2011 
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mice received an intramuscular injection of 10 mg/kg ketoprofen (50 µl in 
each thigh) to prevent inflammation. After implantation, C57/Bl6 mice were 
housed individually and allowed to recover for 1 d. We temporarily removed 
the coverslip and deposited a B16-GFP tumor fragment (1-mm diameter) 
in the middle of the chamber. Mice tolerated the skin-fold chamber well and 
showed no signs of discomfort or changes in sleeping and feeding behavior. 
Mice were given an i.p. injection of 500 µg CL1-R2 or IgG1 control three times 
per week together with 10 mg/kg cyclophosphamide administered in the drink-
ing water. Animals anesthetized with 2% isoflurane were analyzed by intravi-
tal microscopy on days 0, 2, 5, 7, 9, 12, and 14 after the tumors were implanted. 
These observations were performed with a MacroFluo microscope (Leica) 
equipped with wide-field objectives (Plan apo 2× for Z6/Z16 with 0.57×, 
2×, and 4× objectives) and a cooled charge-coupled device camera (Cool-
SNAP HQ; Roper Scientific). Fluorescence excitation was obtained with a 
Mercury arc lamp (HBO; Osram) and a GFP filter (Leica). We used MetaVue 
software (Molecular Devices) for image acquisition. 50 µl of 0.5% tetra-
methylrhodamine  isothiocyanate–labeled  dextran  (TRITC-dextran;  Sigma- 
Aldrich) in PBS was injected intravenously to obtain better contrast when 
viewing vessels. To calculate the tumor area, mean vessel diameter, vascular 
area, and microvessel fractal dimension, digital images were obtained from up 
to five locations within the tumor and analyzed with ImageJ software (1.36b; 
National Institutes of Health). By applying a Gaussian Blur filter and thresh-
old, nonspecific pixels were removed, blood vessels were identified, and vas-
cular areas were calculated. The binary images were reduced to a 1-pixel-wide 
skeleton. We calculated the microvessel fractal dimension with the FracLac 
v2.4e plug-in, available in the Image J environment, using the box-counting 
method. The image was divided into increasingly smaller boxes and the number 
of boxes of size  required to cover the vasculature was counted and indicated 
as N(). Fractal dimension was calculated and indicated as N(). Fractal di-
mension (Df) is given by: Df = lim→0[log N()/log()].
DUS analysis. C57/BL6 mice were injected subcutaneously with 105 B16 
cells and treated 3 d later with i.p. injections (three times per week) of 500 µg 
of either CL1-R2 or control IgG. Cyclophosphamide was added to the 
drinking water. We analyzed changes in the number of intratumoral blood 
vessels by carrying out DUS analysis on days 12, 15, and 18 after the first 
CL1-R2 injection, as previously described (Elie et al., 2007). In brief, mice 
were anesthetized 15 min before each DUS analysis by an i.p. injection of 
0.2 ml of a mixture of 10 mg/ml ketamine (Pfizer) and 0.1% xylazine (Bayer). 
One group of mice received repeated i.p. injections of 500 µg CL1-R2 mAb, 
whereas another group received IgG1 control antibody (five mice per group). 
We performed examinations with a diagnostic ultrasound system (Aplio SSA-
770A; Toshiba) with two high-frequency large-bandwidth probes: 9 MHz (PZT-
PLT 604AT;  Toshiba) and 14 MHz (PZT-PLT1204AT;  Toshiba).  We optimized 
the sonograph settings for small and superficial tumors, and these settings re-
mained unchanged for all examinations. We used a 50.0-mm Eko-Gel high 
polymer ultrasound standoff pad (Eurocamina SRL) between the transducer 
and the tumor surface. Color DUS scans were performed in the power Doppler 
mode for evaluation of the number of blood vessels within tumors. We deter-
mined the number of vessels for multiple cross sections of the tumor.
Histopathology and immunostaining. Human normal or adenocarci-
noma colon biopsies were obtained from P. Brousset (Laboratory of Anatomy 
and  Pathological  Cytology,  Purpan  Hospital, Toulouse,  France).  Grafted 
Matrigel plugs, B16 tumors at day 16, or human colon biopsies specimens 
were fixed in 4% paraformaldehyde and embedded in paraffin. Mouse vessels 
were stained with the biotinylated isolectin B4 (Vector Laboratories) at 1:200 
dilutions and human vessels with the mouse anti-CD31 antibody (Dako) at 
1:200 dilutions, followed by biotinylated rat anti–mouse secondary antibody 
(BD). Immune complexes were visualized using the VECTASTAIN Elite 
ABC system (Vector Laboratories). For CD160 visualization, tumor sections 
were stained with 6 µg/ml of the CL1-R2 anti-CD160 mAb and incubated 
with the TSA tyramide amplification kit (Dako) according to the manufac-
turer’s instructions. For necrosis analysis, B16 tumors sections were stained 
with hematoxylin and eosin. In perfusion experiments, mice received an   
i.v. injection of 40 mg/kg of the fluorescent DNA-binding dye Hoechst 
mouse pups were killed and their eyes enucleated, fixed in 4% paraformalde-
hyde for at least 16 h at 4°C, and embedded in paraffin. We prepared sagittal 
5-µm sections with a microtome (HM355, MICROM MICROTEC), stained 
sections with periodic acid–Schiff reagent, and counterstained with hematox-
ylin and eosin. We counted five to eight sections on each side of the optic 
nerve. Two trained investigators blindly counted the number of neovascular 
endothelial cells and vessel lumens across the entire retinal sample in each in-
tact section at 100× magnification. Mean numbers of endothelial cell nuclei 
and vessel numbers were determined using a Poisson regression model for 
clustered data. 95% confidence intervals of the mean number estimates are 
figured as error bars. P-values were corrected for post-hoc group compari-
sons by the Bonferroni method. Endothelial cell–specific staining was per-
formed  by  immunohistofluorescence.  Paraffin  was  removed  and  sections 
were rehydrated and incubated for 20 min in 1× citrate buffer in a microwave 
at 500 W. Sections were treated with 0.3% Triton X-100 for 5 min and then 
incubated overnight with polyclonal antibody raised against Von Willebrand 
Factor at a 1:500 dilution (Abcam). Negative control immunohistochemical 
experiments were systematically performed with the exclusive omission of 
primary antibody. Sections were then incubated for 2 h at room temperature 
with a secondary Alexa Fluor 488 anti–sheep antibody at a 1:300 dilution (In-
vitrogen). After counterstaining for 10 min with DAPI at a 1:1,000 dilution 
(Sigma-Aldrich), washed sections were mounted in Fluorescent Mounting 
Medium (Dako). Optically sectioned images were acquired by confocal laser-
scanning microscopy (LSM 700; Carl Zeiss).
In vivo Matrigel plug angiogenesis assays. 500-µl Matrigel plugs (BD), 
supplemented with 600 ng/ml FGF2 (R & D Systems) and 25 µg of either 
CL1-R2 mAb or an IgG1 isotype control, were injected subcutaneously into 
the two flanks of BALB/c mice. Every other day, 200 µg CL1-R2 mAb or 
IgG1 mAb was injected in vivo directly into the Matrigel plug through the 
skin. 7 d after injection, the animals were killed, the plugs removed, and their 
hemoglobin concentration evaluated sing Drabkin’s reagent kit (Sigma-Aldrich). 
For histological analyses, Matrigel plugs were fixed in 4% paraformaldehyde 
and embedded in paraffin. Sections were stained by incubation with biotinyl-
ated isolectin B4 (Vector Laboratories) followed by streptavidin-peroxidase 
and DAB substrate.
B16 tumor model and treatment schedule. Mouse B16 tumor cells ex-
pressing GFP (a gift from J. Di Santo [Institut Pasteur, Paris] and B. Couderc 
[Institut National de la Santé et de la Recherche Médicale U563, Toulouse, 
France]) were injected subcutaneously into the flanks of C57BL/6 mice   
(105 cells per mouse). These mice received i.p. injections of 500 µg CL1-
R2 mAb or IgG1 control or an equivalent volume (100 µl) of PBS three 
times per week starting on the day of tumor inoculation. Mice were also 
treated with 10 mg/kg body weight of cyclophosphamide (Sigma-Aldrich) 
administered daily in the drinking water. No apparent signs of toxicity, such 
as weight loss or lethargy, were observed in response to treatment. Tumor 
volume was determined three times per week by measurement with calipers. 
The volume was calculated as width2 × length × 0.52.
Tropomyosin 3 (TPM3)–ALK MEF tumor model. Mouse MEF fibro-
blasts expressing the active mutant form of the nonmuscular TPM3-ALK were 
injected subcutaneously into nude mice as previously described (Giuriato et al., 
2007). Mice were randomized in four treatment groups of five mice each that 
received IgG1 control, cyclophosphamide, CL1-R2, or CL1-R2 combined to 
cyclophosphamide (same protocol and doses as the B16 tumor model described 
in the previous section). Treatments were stated the same day as tumor implan-
tation. Growing tumors were harvested 21 d later, fixed, and paraffin embed-
ded for subsequent immunohistochemical or confocal microscopy analysis.
Dorsal skin-fold chamber model and intravital microscopy. The experi-
mental protocol was similar to that used in previous studies (Makale, 2007). 
C57BL/6 mice were anesthetized, and then a double layer of skin was 
sandwiched between two titanium frames and a layer of skin was surgically 
removed to create an observation window that was then covered with a glass 
coverslip with a 12-mm diameter. At the end of the surgery and the day after, 984 Antiangiogenic therapy targeted to CD160 | Chabot et al.
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